- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02582125
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
April 19, 2022 updated by: Ono Pharmaceutical Co. Ltd
ONO-4538 Multicenter, Open-label, Single-arm, Phase II Study in Advanced Non-small Cell Lung Cancer
The objective of the study is to investigate the safety and efficacy of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung, Taiwan
- Taichung Clinical Site 1
-
Taichung, Taiwan
- Taichung Clinical Site 2
-
Tainan, Taiwan
- Tainan Clinical Site 1
-
Tainan, Taiwan
- Tainan Clinical Site 2
-
Tainan, Taiwan
- Tainan Clinical Site 3
-
Taipei, Taiwan
- Taipei Clinical Site 1
-
Taipei, Taiwan
- Taipei Clinical Site 2
-
Taipei, Taiwan
- Taipei Clinical Site 3
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female ≥ 20 years of age
- Histologically or cytologically confirmed non-small cell lung cancer
- Diagnosis of NSCLC in stage IIIB/IV unsuited to radical radiotherapy according to UICC-TNM classification (7th edition) or recurrent NSCLC
- Has at least one measurable lesion, as defined by the RECIST guideline (version 1.1)
Exclusion Criteria:
- Current or prior severe hypersensitivity to another antibody product
- Multiple primary cancers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ONO-4538
ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety (Adverse events, Laboratory tests, Vital signs, ECG, Chest X-ray, ECOG)
Time Frame: Approximately 6 months
|
Approximately 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate (centrally assessed)
Time Frame: Approximately 6 months
|
Approximately 6 months
|
Response rate (study site assessment by investigator)
Time Frame: Approximately 6 months
|
Approximately 6 months
|
Overall survival
Time Frame: Approximately 1 year
|
Approximately 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 27, 2016
Primary Completion (Actual)
January 4, 2021
Study Completion (Actual)
December 31, 2021
Study Registration Dates
First Submitted
October 20, 2015
First Submitted That Met QC Criteria
October 20, 2015
First Posted (Estimate)
October 21, 2015
Study Record Updates
Last Update Posted (Actual)
April 27, 2022
Last Update Submitted That Met QC Criteria
April 19, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- ONO-4538-25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedNon-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung CancerUnited States
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
Clinical Trials on ONO-4538
-
Ono Pharmaceutical Co. LtdCompletedAdvanced or Metastatic Solid TumorsJapan
-
Ono Pharmaceutical Co. LtdActive, not recruitingAdvanced or Metastatic Solid TumorsJapan
-
Ono Pharmaceutical Co. LtdCompletedAdvanced Solid Tumors | Recurrent Solid TumorsKorea, Republic of
-
Dan ZandbergBristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and NeckUnited States
-
Ono Pharmaceutical Co. LtdCompletedMalignant Solid TumorJapan
-
Ono Pharmaceutical Co. LtdCompletedGastric CancerJapan, Korea, Republic of, Taiwan
-
Ono Pharmaceutical Co. LtdCompletedAdvanced Solid Tumors | Recurrent Solid TumorsKorea, Republic of
-
Ono Pharmaceutical Co. LtdCompletedAdvanced Non-small Cell Lung CancerKorea, Republic of
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbActive, not recruitingMelanoma (Skin)United States
-
Osaka UniversityOno Pharmaceutical Co. Ltd; Kyowa Kirin Co., Ltd.; Clinical Study Support, Inc.; Fiverings Co., Ltd...CompletedGastric Cancer | Esophageal Cancer | Lung Cancer | Renal Cancer | Oral CancerJapan